World’s first Alzheimer’s patient receives amyloid-targeting therapy (outside US) at FUH

In a remarkable medical achievement, Fakeeh University Hospital in Dubai has initiated the world’s first treatment of an Alzheimer’s patient using a novel amyloid-targeting therapy. This milestone represents a major step forward in the global fight against Alzheimer’s disease, offering new hope for patients and their families. This innovative therapy is designed to target and reduce amyloid plaques in the brain, a hallmark of Alzheimer’s disease.

It has demonstrated the potential to slow cognitive decline, particularly in patients diagnosed with early-stage mild cognitive impairment (MCI), who are most likely to benefit from early intervention. At Fakeeh University Hospital, the patient was carefully selected through the use of advanced diagnostic tools and assessments, ensuring the highest likelihood of success. The patient is in the early stages of MCI, reflecting the hospital’s commitment to early and precise intervention in neurodegenerative diseases.



A multidisciplinary team at Fakeeh University Hospital has crafted a personalised care plan, featuring continuous monitoring and tailored support. The goal is to slow the disease's progression and enhance the patient's quality of life during the initial stages of Alzheimer’s. For more information, please visit: fuh.

care.